You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
衞信康(603676.SH)獲複方電解質注射液(Ⅱ)《藥品註冊批件》
格隆匯 01-03 16:23

格隆匯1月3日丨衞信康(603676.SH)公佈,全資子公司內蒙古白醫製藥股份有限公司近日收到國家藥品監督管理局核准簽發的複方電解質注射液(Ⅱ)《藥品註冊批件》。

複方電解質注射液(Ⅱ)為含多種電解質的注射劑,適用於治療伴隨或預期出現酸中毒的等滲性脱水,補充細胞外液的丟失。複方電解質注射液(Ⅱ)的原研產品為“Sterofundin®ISO”,最早於2003年10月在德國獲批上市,已於2012年11月22日獲批向我國進口。

截至2019年12月31日,複方電解質注射液(II)項目已投入研發費用約786.35萬元人民幣。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account